Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis

被引:175
作者
Honda, T
Segi-Nishida, E
Miyachi, Y
Narumiya, S [1 ]
机构
[1] Kyoto Univ, Dept Pharmacol, Kyoto 6068501, Japan
[2] Kyoto Univ, Fac Med, Dept Dermatol, Kyoto 6068501, Japan
关键词
D O I
10.1084/jem.20051310
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Prostaglandin (PG)I-2 (prostacyclin [PGI]) and PGE(2) are abundantly present in the synovial fluid of rheumatoid arthritis ( RA) patients. Although the role of PGE(2) in RA has been well studied, how much PGI(2) contributes to RA is little known. To examine this issue, we back-crossed mice lacking the PGI receptor (IP) to the DBA/1J strain and subjected them to collagen-induced arthritis (CIA). IP-deficient (IP-/-) mice exhibited significant reduction in arthritic scores compared with wild-type (WT) mice, despite anti-collagen antibody production and complement activation similar to WT mice. IP-/- mice also showed significant reduction in contents of proinflammatory cytokines, such as interleukin (IL)-6 in arthritic paws. Consistently, the addition of an IP agonist to cultured synovial fibroblasts significantly enhanced IL-6 production and induced expression of other arthritis-related genes. On the other hand, loss or inhibition of each PGE receptor subtype alone did not affect elicitation of inflammation in CIA. However, a partial but significant suppression of CIA was achieved by the combined inhibition of EP2 and EP4. Our results show significant roles of both PGI(2)-IP and PGE(2)-EP2/EP4 signaling in the development of CIA, and suggest that inhibition of PGE(2) synthesis alone may not be sufficient for suppression of RA symptoms.
引用
收藏
页码:325 / 335
页数:11
相关论文
共 53 条
[1]   INTERLEUKIN-6 IN BIOLOGY AND MEDICINE [J].
AKIRA, S ;
TAGA, T ;
KISHIMOTO, T .
ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 :1-78
[2]   Interleukin 6 is required for the development of collagen-induced arthritis [J].
Alonzi, T ;
Fattori, E ;
Lazzaro, D ;
Costa, P ;
Probert, L ;
Kollias, G ;
De Benedetti, F ;
Poli, V ;
Ciliberto, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (04) :461-468
[3]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[4]   THE SYNOVIAL PROSTAGLANDIN SYSTEM IN CHRONIC INFLAMMATORY ARTHRITIS - DIFFERENTIAL-EFFECTS OF STEROIDAL AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS [J].
BOMBARDIERI, S ;
CATTANI, P ;
CIABATTONI, G ;
DIMUNNO, O ;
PASERO, G ;
PATRONO, C ;
PINCA, E ;
PUGLIESE, F .
BRITISH JOURNAL OF PHARMACOLOGY, 1981, 73 (04) :893-901
[5]   IS PROSTACYCLIN THE MAJOR PRO-INFLAMMATORY PROSTANOID IN JOINT FLUID [J].
BRODIE, MJ ;
HENSBY, CN ;
PARKE, A ;
GORDON, D .
LIFE SCIENCES, 1980, 27 (07) :603-608
[6]   ADAM8: A novel osteoclast stimulating factor [J].
Choi, SJ ;
Han, JH ;
Roodman, GD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (05) :814-822
[7]   CYCLOOXYGENASE-1 AND CYCLOOXYGENASE-2 EXPRESSION IN RHEUMATOID SYNOVIAL TISSUES - EFFECTS OF INTERLEUKIN-1-BETA, PHORBOL ESTER, AND CORTICOSTEROIDS [J].
CROFFORD, LJ ;
WILDER, RL ;
RISTIMAKI, AP ;
SANO, H ;
REMMERS, EF ;
EPPS, HR ;
HLA, T .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (03) :1095-1101
[8]   The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis [J].
Dayer, JM .
RHEUMATOLOGY, 2003, 42 :3-10
[9]   Rheumatoid arthritis [J].
Feldmann, M ;
Brennan, FM ;
Maini, RN .
CELL, 1996, 85 (03) :307-310
[10]   Evolving concepts of rheumatoid arthritis [J].
Firestein, GS .
NATURE, 2003, 423 (6937) :356-361